PSG Stock Overview
Manufactures and sells over-the-counter drugs and other healthcare products in Germany. More details
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 3/6 |
Past Performance | 4/6 |
Financial Health | 5/6 |
Dividends | 4/6 |
PharmaSGP Holding SE Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €24.40 |
52 Week High | €27.00 |
52 Week Low | €18.00 |
Beta | -0.10 |
11 Month Change | 3.39% |
3 Month Change | 18.45% |
1 Year Change | 24.17% |
33 Year Change | -1.21% |
5 Year Change | n/a |
Change since IPO | -31.46% |
Recent News & Updates
Recent updates
Shareholder Returns
PSG | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | -0.8% | -6.3% | -0.6% |
1Y | 24.2% | -21.6% | 9.6% |
Return vs Industry: PSG exceeded the German Pharmaceuticals industry which returned -20.4% over the past year.
Return vs Market: PSG exceeded the German Market which returned 7.8% over the past year.
Price Volatility
PSG volatility | |
---|---|
PSG Average Weekly Movement | 5.9% |
Pharmaceuticals Industry Average Movement | 8.1% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 11.0% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PSG has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: PSG's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 89 | Natalie Weigand | pharmasgp.com |
PharmaSGP Holding SE manufactures and sells over-the-counter drugs and other healthcare products in Germany. The company’s pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage creams for the treatment of various pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Revitensin, a drug for the treatment of hair loss; Dorisol for neuralgia (nerve pain), headaches, and migraines; Fulminan, a beauty drink; Lindaven, a pharmaceutical drops to treat their unpleasant problem; and SCLEROCALMAN, a drug for the treatment of clogged cerebral blood vessels. It also offers Prostacalman, a medication for cystitis and urination discomfort in a benign enlarged prostate; Revoten for women with weak connective tissue; Mindalin, a micronutrient drink for a healthy cardiovascular system; MELISTON, a prescription-free tablets to treat anxiety, restlessness, and mood swings; Deruba, a cream for skin redness; Lentisol that prevents the formation of new pigment spots; Neodolor, a headache tablet; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo.
PharmaSGP Holding SE Fundamentals Summary
PSG fundamental statistics | |
---|---|
Market cap | €302.15m |
Earnings (TTM) | €18.21m |
Revenue (TTM) | €109.76m |
16.6x
P/E Ratio2.8x
P/S RatioIs PSG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PSG income statement (TTM) | |
---|---|
Revenue | €109.76m |
Cost of Revenue | €9.98m |
Gross Profit | €99.78m |
Other Expenses | €81.57m |
Earnings | €18.21m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 28, 2024
Earnings per share (EPS) | 1.52 |
Gross Margin | 90.91% |
Net Profit Margin | 16.59% |
Debt/Equity Ratio | 212.5% |
How did PSG perform over the long term?
See historical performance and comparison